医药生物/化学制药 数据来源：聚源 国邦医药（605507.SH） 2025Q2 业绩超预期，动保板块迎来大幅增长 2025 年 07 月 31 日 投资评级：买入（维持） | 日期 | 2025/7/30 | | --- | --- | | 当前股价(元) | 23.68 | | 一年最高最低(元) | 23.68/15.81 | | 总市值(亿元) | 132.33 | | 流通市值(亿元) | 71.45 | | 总股本(亿股) | 5.59 | | 流通股本(亿股) | 3.02 | | 近 3 个月换手率(%) | 71.22 | 股价走势图 -16% 0% 16% 32% 48% 2024-07 2024-11 2025-03 国邦医药 沪深300 相关研究报告 《2025Q1 业绩稳健增长，动保原料药 迎来周期拐点—公司信息更新报告》 -2025.4.16 《2024 年业绩快速增长，动保原料药 迎来周期拐点—公司信息更新报告》 -2025.3.28 《医药板块稳健增长，动保原料药有 望迎来周期拐点—公司首次覆盖报 告》-2025.3.17 余汝意（分析师） 阮帅（分析师） yuruyi@kys ...

通过天眼查大数据分析，国邦医药集团股份有限公司共对外投资了14家企业，参与招投标项目533次， 知识产权方面有商标信息4条，专利信息244条，此外企业还拥有行政许可3个。 来源：金融界 国邦医药最新一期业绩显示，截至2025中报，公司营业总收入30.26亿元、同比增长4.63%，归属净利润 4.56亿元，同比增长12.60%，扣非净利润4.36亿元，同比增长10.33%，流动比率2.711、速动比率 2.039、资产负债率25.41%。 天眼查商业履历信息显示，国邦医药集团股份有限公司，成立于1996年，位于绍兴市，是一家以从事医 药制造业为主的企业。企业注册资本55882.35万人民币，实缴资本55882.35万人民币。公司法定代表人 为邱家军。 金融界消息 截至2025年7月30日收盘，国邦医药（605507）报收于23.68元，上涨9.99%，换手率5.3%， 成交量16.00万手，成交金额3.75亿元。 资金流向方面，今日主力资金净流入8505.82万元，占比成交额22.68%。其中，超大单净流入9106.75万 元、占成交额24.29%，大单净流出600.93万元、占成交额1.6%，中单净流出流出4 ...

Core Insights - Guobang Pharmaceutical (605507.SH) reported a total revenue of 3.026 billion yuan for the first half of 2025, marking an increase of 134 million yuan or 4.63% year-on-year, achieving five consecutive years of growth [1] - The net profit attributable to shareholders reached 456 million yuan, up by 50.97 million yuan or 12.60% year-on-year, indicating two consecutive years of profit growth [1] - The net cash inflow from operating activities was 103 million yuan, an increase of 353 million yuan compared to the same period last year [1] Financial Metrics - The latest debt-to-asset ratio stands at 25.41%, a decrease of 0.28 percentage points from the previous quarter [3] - The gross profit margin is reported at 26.85%, an increase of 0.42 percentage points from the previous quarter and up by 0.26 percentage points year-on-year, achieving two consecutive quarters of growth [3] - The return on equity (ROE) is 5.65%, an increase of 0.31 percentage points compared to the same period last year [3] - The diluted earnings per share (EPS) is 0.82 yuan, an increase of 0.09 yuan or 12.33% year-on-year, marking two consecutive years of growth [3] Operational Efficiency - The total asset turnover ratio is 0.28 times, while the inventory turnover ratio is 1.55 times [4] - The number of shareholders is 25,000, with the top ten shareholders holding 357 million shares, accounting for 63.85% of the total share capital [4] - The largest shareholder is Xinchang Ander Trading Co., Ltd., holding 23.08% of the shares [4]

Core Insights - Guobang Pharmaceutical (605507.SH) reported its 2025 mid-year financial results, highlighting a total revenue of 3.026 billion yuan and a net profit attributable to shareholders of 456 million yuan [2]. Financial Performance - The company's total revenue reached 3.026 billion yuan, with a net profit of 456 million yuan [2]. - Operating cash flow showed a net inflow of 103 million yuan [2]. - The latest gross profit margin was recorded at 26.85%, while the return on equity (ROE) stood at 5.65% [5]. - The diluted earnings per share were reported at 0.82 yuan [6]. Balance Sheet Metrics - The current asset-liability ratio is 25.41%, which reflects an increase of 0.52 percentage points compared to the same period last year [4]. - The total asset turnover ratio remained stable year-on-year, although it decreased by 0.88% compared to the previous year [6]. - The inventory turnover ratio was 1.55 times, showing a decrease of 0.02 times year-on-year, which is a decline of 0.97% compared to the same period last year [6]. Shareholder Structure - The number of shareholders is approximately 25,000, with the top ten shareholders holding a total of 357 million shares, accounting for 63.85% of the total share capital [6]. - The largest shareholder is Xinchang Ander Trading Co., Ltd., holding 23.08% of the shares [6].

Core Viewpoint - Guobang Pharmaceutical's performance in the first half of 2025 reflects growth driven by core business deepening, continuous R&D investment, and collaborative efforts in upgrading the industrial chain [2] Financial Performance - In the first half of 2025, Guobang Pharmaceutical achieved operating revenue of 3.026 billion yuan, a year-on-year increase of 4.63% - The net profit attributable to shareholders reached 456 million yuan, representing a year-on-year growth of 12.60% [1] Business Segments - The company maintains a leading position in pharmaceutical raw materials, with significant achievements in animal health, plant protection, and food-drug homologation sectors [1] - The animal health business has seen a notable decrease in marginal costs due to scale advantages, with over 2,000 tons of florfenicol shipped and a growing market share [1] - The plant protection project has successfully entered trial production, and the Seven Fang Cup series health drinks have been launched in the market [1] Market Expansion and Global Strategy - Guobang Pharmaceutical's products are distributed across 117 countries and regions on six continents, with over 5,000 supply partners [2] - The company actively participated in 18 domestic and international exhibitions, including API and CPHI, to expand its global market channels [2] - The proportion of products certified by international authorities continues to rise, with 18 products having obtained CEP certification and 7 products approved by the FDA [2] Cash Flow and Operational Quality - The net cash flow from operating activities turned positive to 103 million yuan, indicating a significant improvement in the company's operational quality [2] - The robust cash flow situation supports ongoing R&D investments, new product pipeline advancements, and capacity expansion [2] R&D and Certification - The company is increasing its investment in R&D and production management, aiming to expand the coverage of international certifications such as CEP and FDA [3]

分组1 - Shijia Photon reported a revenue of 993 million yuan for the first half of the year, a year-on-year increase of 121.12% [1] - The net profit attributable to shareholders reached 217 million yuan, reflecting a significant year-on-year growth of 1712% [1] - The company has successfully developed new products for data centers and AI computing, including high-power CWDFB lasers and high-temperature FAU devices [1] 分组2 - Hunan Tianyan announced that China Changan Automobile has become its indirect controlling shareholder after a division of the Weaponry Equipment Group [2] - Following the division, China Changan Automobile holds 37.25% of Hunan Tianyan through Chen Zhi Group, maintaining the actual controller as the State-owned Assets Supervision and Administration Commission [2] 分组3 - Dong'an Power stated that its indirect controlling shareholder has changed to China Changan Automobile after the division of the Weaponry Equipment Group [2] - China Changan Automobile now holds 50.93% of Dong'an Power's total shares through Chen Zhi Group [2] 分组4 - Wantong Intelligent signed an exclusive authorization agreement with Shanghai Shenming Aosi Semiconductor Technology, allowing it to produce and sell boards based on the Fellow 1 model chip for five years [3] - This collaboration is expected to positively impact the company's future operations and aligns with its long-term development strategy [3] 分组5 - WuXi AppTec plans to adjust the upper limit for its share repurchase price from 90.72 yuan to 114.15 yuan per share [4] 分组6 - Xinya Electronics reported that the revenue from high-frequency and high-speed copper cable connectors accounted for only 3.31% of its total revenue as of the 2024 annual report [5] - The company experienced abnormal stock trading fluctuations with a cumulative price deviation exceeding 20% over three consecutive trading days [5] 分组7 - Huajin Technology plans to acquire 6% of Crystal Integrated's shares for a total price of 2.393 billion yuan, with a transfer price of 19.88 yuan per share [6] - This transaction does not constitute a related party transaction or a major asset restructuring [6] 分组8 - Fangbang Co. reported that the sales revenue from its peelable copper products accounted for less than 0.3% of its main business revenue in the first half of the year [8] - The company is monitoring potential market demand increases due to the adoption of CoWoP technology by leading overseas companies [8]

证券代码：605507 证券简称：国邦医药 公告编号：2025-034 国邦医药集团股份有限公司 关于 2025 年半年度募集资金存放与使用情况专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 经中国证券监督管理委员会《关于核准国邦医药集团股份有限公司首次公开 发行股票的批复》（证监许可〔2021〕2353 号）核准，国邦医药集团股份有限 公司（以下简称"公司"或"国邦医药"）首次公开发行人民币普通股（A 股） 83,823,500 股，发行价格为人民币 32.57 元/股，募集资金总额为人民币 2,730,131,395.00 元，扣除不含增值税发行费用人民币 85,403,348.45 元后，募集 资金净额为人民币 2,644,728,046.55 元。上述募集资金已于 2021 年 7 月 28 日到 账，立信会计师事务所（特殊普通合伙）对募集资金到位情况进行了审验，并出 具了《验资报告》（信会师报字[2021]第 ZF10803 号）。 （二）募集资金 ...

国邦医药集团股份有限公司(以下简称"公司")第二届监事会第十二次会议 于 2025 年 7 月 19 日以书面及邮件等方式发出通知和会议材料，并于 2025 年 7 月 29 日在公司会议室以通讯的方式召开。会议应出席监事 3 人，实际出席会议 的监事 3 人，会议由监事会主席孟仲建先生主持。本次监事会会议的召集、召开 和表决程序符合有关法律、行政法规、部门规章、规范性文件和《公司章程》的 规定。经会议审议，全体监事审议通过了如下议案。 第二届监事会第十二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 证券代码：605507 证券简称：国邦医药 公告编号：2025-033 国邦医药集团股份有限公司 二、监事会会议审议情况 具体内容详见公司披露于上海证券交易所网站（www.sse.com.cn）的《国邦 医药关于 2025 年半年度募集资金存放与使用情况专项报告》（公告编号： 2025-034）。 （一）审议通过《关于 2025 年半年度报告及摘要的议案》 表决结果：同意 3 票，反对 0 ...

证券代码：605507 证券简称：国邦医药 公告编号：2025-032 国邦医药集团股份有限公司 第二届董事会第十四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 （一）审议通过《关于 2025 年半年度报告及摘要的议案》 表决结果：同意 9 票，反对 0 票，弃权 0 票。 具体内容详见公司披露于上海证券交易所网站（www.sse.com.cn）的《国邦 医药 2025 年半年度报告》及《国邦医药 2025 年半年度报告摘要》。 在提交本次董事会审议前，本议案已经董事会审计委员会审议通过。 （二）审议通过《关于 2025 年半年度募集资金存放与使用情况专项报告的 议案》 表决结果：同意 9 票，反对 0 票，弃权 0 票。 具体内容详见公司披露于上海证券交易所网站（www.sse.com.cn）的《国邦 医药关于 2025 年半年度募集资金存放与使用情况专项报告》（公告编号： 2025-034）。 特此公告。 国邦医药集团股份有限公司(以下简称"公司")第二届董事会第十四次会议 于 2 ...

国邦医药集团股份有限公司2025 年半年度报告 公司代码：605507 公司简称：国邦医药 国邦医药集团股份有限公司 2025 年半年度报告 1 / 168 国邦医药集团股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人邱家军、主管会计工作负责人龚裕达及会计机构负责人（会计主管人员）石兴 成声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中涉及的未来计划、发展战略等前瞻性陈述不构成公司对投资者的实质承诺，敬请投 资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 ...